TEVA Stock Risk & Deep Value Analysis

Teva Pharmaceutical Industries Ltd

Healthcare • Drug Manufacturers - Specialty & Generic

DVR Score

0.5

out of 10

Distressed

What You Need to Know About TEVA Stock

We analyzed Teva Pharmaceutical Industries Ltd using our deep value framework. Sign in to see our full verdict and DVR Score.

We ran TEVA through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Moderate. Here's what we found.

Updated Mar 17, 2026•Run Fresh Analysis →

TEVA Risk Analysis & Red Flags

Risk Matrix

Overall

Moderate

Financial

Medium

Market

Medium

Competitive

High

Execution

Medium

Regulatory

High

Upcoming Risk Events

📅
Unfavorable outcomes in ongoing or new litigation
📅
Increased competitive pressure in generics, leading to price erosion
📅
Clinical trial failures or regulatory setbacks for pipeline products
📅
Macroeconomic headwinds impacting pharmaceutical demand or pricing

Unlock TEVA Risk Analysis & Red Flags

Create a free account to see the full analysis

What Does Teva Pharmaceutical Industries Ltd (TEVA) Do?

Market Cap

$36.59B

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Employees

33,892

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO to treat neurodegenerative and movement disorders chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv-Yafo, Israel.

Visit Teva Pharmaceutical Industries Ltd Website

Investment Thesis

Teva is a pharmaceutical turnaround story successfully navigating debt reduction and shifting towards a more profitable specialty and biosimilar product mix. While it offers potential for moderate capital appreciation through operational efficiency and targeted growth, its large-cap status and reliance on mature markets make a 10x growth trajectory within 3-5 years highly improbable. It's a potential value play rather than a high-growth opportunity.

Is TEVA Stock Undervalued?

Teva Pharmaceutical continues its successful turnaround, as reflected in its current significant market capitalization of $108.19B. Key specialty products like Austedo and Ajovy demonstrate stable growth, positively impacting the company's outlook and financial stability. However, despite these operational improvements and debt reduction efforts, Teva's core business model, heavily reliant on the mature and competitive generics market, significantly limits its 10x growth potential within the next 3-5 years from its current large-cap valuation. Achieving a market cap of over $1.08 trillion ($108.19B * 10) necessitates disruptive innovation or explosive market expansion not currently evident in Teva's strategic vision or pipeline. While a stabilization success story, it lacks the foundational elements for aggressive, exponential growth from its current base. The score remains consistent with the previous analysis due to no material changes fundamentally altering this long-term growth ceiling within the last 55 days.

Unlock the full AI analysis for TEVA

Get the complete DVR score, risk analysis, and more

TEVA Price Targets & Strategy

12-Month Target

$35.00

Bull Case

$42.00

Bear Case

$25.00

Entry Strategy

Consider dollar-cost averaging in the $28-$30 range, or buying on dips below $29.00.

Exit Strategy

Take partial profits at $35.00 and $40.00. Set a stop-loss at $27.00 to protect capital.

Portfolio Allocation

1-3% (Conservative), 3-7% (Moderate), 7-15% (Aggressive) – This allocation applies to a 'value/turnaround' segment of a portfolio, not specifically for 10x growth potential.

Price Targets & Strategy

Upgrade to Premium for price targets and entry/exit strategies

Is TEVA Financially Healthy?

Valuation

P/E Ratio

52.28

Price/Book

5.05

Does TEVA Have a Competitive Moat?

Moat Rating

🛡️ Narrow

Moat Trend

Stable

Moat Sources

3 Identified

Intangible Assets/IPCost AdvantagesEfficient Scale

Teva's narrow moat is derived from its intellectual property for specialty drugs, which provides temporary market exclusivity, and its vast scale and efficient operations in the generics sector. While these elements provide a competitive edge, the generics market faces constant pricing pressure and specialty patents eventually expire, limiting the moat's long-term durability.

Moat Erosion Risks

•Patent expirations on key specialty products (e.g., Austedo, Ajovy)
•Aggressive pricing pressure and increased competition in the generics market
•Ongoing regulatory scrutiny and potential legal liabilities (e.g., antitrust, opioid litigations)

TEVA Competitive Moat Analysis

TEVA Market Intelligence

Sentiment & Insider Activity

Social Sentiment

Neutral

Institutional Sentiment

Neutral-Positive

Insider Activity (Form 4)

No significant recent insider buying or selling activity (past 3 months) reported.

Options Flow

Neutral options activity with relatively balanced call and put volumes, indicating no strong directional conviction from institutional traders.

Earnings Intelligence

Next Earnings

Estimated early May 2026 (Q1 2026)

Surprise Probability

Medium

Historical Earnings Pattern

Stock typically shows modest reaction to earnings, with slight upward trend on beats and downward pressure on misses, consistent with a mature pharmaceutical company. Volatility tends to be linked to guidance or unexpected legal developments.

Key Metrics to Watch

Specialty product sales growth (Austedo, Ajovy)Free Cash Flow (FCF) generationNet debt reduction progressGross Margin expansion

Competitive Position

Top Competitor

VTRS

Market Share Trend

Stable overall; Gaining market share in specific specialty areas (e.g., Austedo, Ajovy) while maintaining or slightly eroding share in mature generics markets due to intense competition.

Valuation vs Peers

Trading at a slight discount on P/E and EV/EBITDA compared to specialty pharma peers, but generally in line with or at a slight premium to pure-play generics due to its hybrid portfolio.

Competitive Advantages

•Broad and diversified generics product portfolio
•Established global distribution and manufacturing network
•Key patent-protected specialty drugs (e.g., Austedo, Ajovy, biosimilars)

Market Intelligence

Get sentiment, earnings intel, and peer analysis with Premium

What Could Drive TEVA Stock Higher?

Near-Term (0-6 months)

•Q1 2026 Earnings Report (Estimated early May 2026)
•Updates on Austedo and Ajovy sales performance
•Progress on biosimilar pipeline filings or approvals

Medium-Term (6-18 months)

•Further significant debt reduction milestones
•Potential new specialty product launches in 2027
•Resolution of any remaining major legal liabilities

Long-Term (18+ months)

•Successful pivot towards a higher-margin specialty and biosimilar-focused portfolio
•Strategic M&A to expand growth segments
•Sustainable operational efficiency improvements

Catalysts & Growth Drivers

Upgrade to Premium to see catalysts

What's the Bull Case for TEVA?

✓
Acceleration in sales growth for Austedo and Ajovy
✓
Significant improvements in the net debt to EBITDA ratio
✓
Successful progression and commercialization of new biosimilar or specialty pipeline assets

Bull Case Analysis

See what could go right with Premium

Competing with TEVA

See how Teva Pharmaceutical Industries Ltd compares to related companies

Company	Market Cap	DVR Score	P/E	Revenue	Profit Margin	Rev Growth
Teva Pharmaceutical Industries Ltd TEVA	$36.6B	0.5	52.3	—	—	—
Pfizer Inc PFE	$161.1B	0.2	20.2	$17.6B	12.4%	-1.7%	Compare →

📊 Explore More Stock Analysis

Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.

Analyze Any Stock →View Top 100 Deep Value Stocks →

FAQ

What is the DVR Score for Teva Pharmaceutical Industries Ltd (TEVA)?

As of March 17, 2026, Teva Pharmaceutical Industries Ltd has a DVR Score of 0.5 out of 10, placing it in the "Distressed" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.

What is the market capitalization of Teva Pharmaceutical Industries Ltd?

Teva Pharmaceutical Industries Ltd's market capitalization is approximately $36.6B. The company operates in the Healthcare sector within the Drug Manufacturers - Specialty & Generic industry.

What ticker symbol does Teva Pharmaceutical Industries Ltd use?

TEVA is the ticker symbol for Teva Pharmaceutical Industries Ltd. The company trades on the NYQ.

What is the risk level for TEVA stock?

Our analysis rates Teva Pharmaceutical Industries Ltd's overall risk as Moderate. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.

What is the P/E ratio of TEVA?

Teva Pharmaceutical Industries Ltd currently has a price-to-earnings (P/E) ratio of 52.3. This is above the market average, suggesting the stock may be priced for high growth expectations.

How often is the TEVA DVR analysis updated?

Our AI-powered analysis of Teva Pharmaceutical Industries Ltd is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on March 17, 2026.

Important Disclaimer – Not Financial Advice

Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for TEVA (Teva Pharmaceutical Industries Ltd) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.

All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.